TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1683545

Group type: EXPERIMENTAL
Intervention: 25 g of activated charcoal administered simultaneously with 400 mg amiodarone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 25 g of activated charcoal administered 1.5 hours after 400 mg amiodarone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group with 400 mg amiodarone and water only
Number of subjects: 18
Study: 7009592

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31331292

Group type: EXPERIMENTAL
Intervention: Massachusetts Child Psychiatry Access Program (MCPAP) for Moms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM) which includes MCPAP for Moms plus a proactive, multifaceted, practice-level intervention with intensive implementation support
Number of subjects: 0
Study: 30646029

Group type: EXPERIMENTAL
Intervention: Greening intervention
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Greening intervention (for participants below the poverty line)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Trash cleanup intervention
Number of subjects: 442

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 442
Study: 27427800

Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO®)
Number of subjects: 238

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 238
Study: 24760261

Group type: EXPERIMENTAL
Intervention: Lower fat diet
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intervention groups (lower fat and lower carbohydrate)
Number of subjects: 227
Study: 22371872

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (individual counseling from health educators to promote physical activity with a healthful diet)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Usual care (advice from physicians about lifestyle for obesity reduction)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (for men)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (for women)
Number of subjects: 490
Study: 20382428

Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory drug (ketorolac)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topical steroid (fluorometholone)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 61
Study: 18351473

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study: 16227648

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 54
Study: 14646439

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel (Instillagel) intraurethrally for approximately 15 min
Number of subjects: 140

Group type: COMPARATOR
Intervention: Water-soluble gel (Aquagel) smeared around the scope and external urethral meatus
Number of subjects: 140
Study: 11279320

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 8878360

Group type: EXPERIMENTAL
Intervention: Training using the Mental Retardation/Developmental Disabilities Adaptation of the Nursing Child Assessment Feeding Scale
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 1994667

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6388170

Group type: EXPERIMENTAL
Intervention: Naftifine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29194847

Group type: EXPERIMENTAL
Intervention: Multifunctional suprapubic catheter (MSC)
Number of subjects: 91
Study: 28114683

Group type: EXPERIMENTAL
Intervention: Level 3 (L3) sleep study
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Level 4 (L4) sleep study
Number of subjects: 406

Group type: COMPARATOR
Intervention: Level 1 (L1) PSG
Number of subjects: 406
Study: 28134604

Group type: EXPERIMENTAL
Intervention: DFDBA and barrier membrane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no buccal grafting)
Number of subjects: 18
Study: 24998121

Group type: EXPERIMENTAL
Intervention: Watchman Left Atrial Appendage Closure device
Number of subjects: 407

Group type: COMPARATOR
Intervention: Chronic warfarin therapy
Number of subjects: 407
Study: 22726232

Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA) for 12 months
Number of subjects: 424
Study: 19233692

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) alone
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Combined deferiprone-deferoxamine (DFP-DFO)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Sequential deferiprone-deferoxamine (DFP-DFO)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 265
Study: 17595355

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg q.d. for 12 weeks followed by 45 mg q.d. for another 12 weeks)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg q.d. followed by 4 mg b.i.d. for the same intervals)
Number of subjects: 735
Study: 15124248

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 10928202

Group type: EXPERIMENTAL
Intervention: Cognitive approach to AIDS education focusing on internal dialogue and self-justifications during high-risk sex decision-making.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled intervention studies confronting gay men with their thinking during high-risk sex.
Number of subjects: 0
Study: 8807687

Group type: EXPERIMENTAL
Intervention: Access to Section 8 rent subsidy certificates
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to Section 8 rent subsidy certificates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive case management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flexible case management services
Number of subjects: 0
Study: 1423953

Group type: EXPERIMENTAL
Intervention: 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo thrombolytic infusion plus full‐dose heparin (group C)
Number of subjects: 149
Study: 4015359

Group type: EXPERIMENTAL
Intervention: Suprapubic tapping
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Suprapubic jabbing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cutaneous stimulation of the thigh
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 20
Study: 31140907

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + 5% NaOCl
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + Diode
Number of subjects: 95

Group type: COMPARATOR
Intervention: 5% NaOCl
Number of subjects: 95
Study: 29529449

Group type: EXPERIMENTAL
Intervention: Adherence to MMT protocol
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Perceived institutional support
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Negative attitudes towards PWUD
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: National-level MMT training
Number of subjects: 418
Study: 27136622

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly (ew)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 22489516

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traction
Number of subjects: 65
Study: 20819563

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg of body weight, daily) for continuous 7 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 17178185

Group type: EXPERIMENTAL
Intervention: Triptorelin depot-3.75 i.m. (30 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injection (30 patients)
Number of subjects: 60
Study: 16151029

Group type: EXPERIMENTAL
Intervention: Caregiver training
Number of subjects: 232
Study: 12672860

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily for 28 weeks
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 11007727

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8617705

Group type: EXPERIMENTAL
Intervention: Sertraline 100 micrograms plus atenolol 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus atenolol 50 mg
Number of subjects: 10
Study: 1616431

Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 0 mm Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 18 mm Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 38 mm Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 60 mm Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 73 mm Hg
Number of subjects: 9
Study: 3888388

Group type: EXPERIMENTAL
Intervention: vindesine plus cisplatin (vindesine 3 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: vinblastine plus cisplatin (vinblastine 6 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: vinblastine plus cisplatin
Number of subjects: 108
Study: 30621836

Group type: EXPERIMENTAL
Intervention: CPAP therapy with symptoms
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Nonroutine reasons for contact
Number of subjects: 1141
Study: 30249632

Group type: EXPERIMENTAL
Intervention: 2 g of myo-inositol powder, twice daily until delivery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo, twice daily until delivery
Number of subjects: 200
Study: 26827980

Group type: EXPERIMENTAL
Intervention: Duraphat varnish (Colgate‐Palmolive, New York, NY) applied to 6 teeth
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unvarnished control teeth (6 teeth)
Number of subjects: 24
Study: 24660154

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rectal acetaminophen
Number of subjects: 96
Study: 22924336

Group type: EXPERIMENTAL
Intervention: PEG-Citrate-Simethicone (PEG-CS) with bisacodyl
Number of subjects: 408

Group type: COMPARATOR
Intervention: PEG-Ascorbate (PEG-ASC)
Number of subjects: 408
Study: 20229056

Group type: EXPERIMENTAL
Intervention: Eprosartan with other anti-hypertensives (n = 47)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Other anti-hypertensives alone (n = 50)
Number of subjects: 97
Study: 18570547

Group type: EXPERIMENTAL
Intervention: Telemedicine consult prior to face-to-face consultation
Number of subjects: 30

Group type: COMPARATOR
Intervention: No telemedicine consult (control group)
Number of subjects: 30
Study: 18082485

Group type: EXPERIMENTAL
Intervention: 1 daily injection of insulin glargine (titrated to achieve fasting plasma glucose < or = 5.3 mmol/L)
Number of subjects: 12612

Group type: EXPERIMENTAL
Intervention: omega‐3‐acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg)
Number of subjects: 12612

Group type: COMPARATOR
Intervention: standard glycemic care
Number of subjects: 12612

Group type: COMPARATOR
Intervention: identical placebo
Number of subjects: 12612
Study: 15678738

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (LM) airway
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fibreoptic laryngoscopy
Number of subjects: 33
Study: 11726736

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg orally in two doses of 10 mg each, with a 1-h interval)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Septic controls (n=10, not treated with melatonin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy newborns (normal controls, n=10)
Number of subjects: 10
Study: 9323286

Group type: EXPERIMENTAL
Intervention: Single-dose prednisolone (2 mg/kg per day as a single morning dose for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Divided-dose prednisolone (2 mg/kg per day in three divided doses for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Single-dose and divided-dose prednisolone
Number of subjects: 106
Study: 8517508

Group type: EXPERIMENTAL
Intervention: Background infusion (BI) at 1 mg/hr with patient-controlled analgesia (PCA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) alone
Number of subjects: 62
Study: 3705683

Group type: EXPERIMENTAL
Intervention: Diltiazem (3 X 60 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11199945

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus pindolol
Number of subjects: 111

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 111
Study: 29206754

Group type: EXPERIMENTAL
Intervention: Nonceliac wheat sensitivity (NCWS) patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Celiac disease (CD) patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Seronegative celiac disease patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Irritable bowel syndrome (IBS) patients
Number of subjects: 45
Study: 30049473

Group type: EXPERIMENTAL
Intervention: Evocalcet
Number of subjects: 634

Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 634
Study: 26384556

Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Presence of a living will and dying in the setting of full support
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Family minority race
Number of subjects: 2850

Group type: EXPERIMENTAL
Intervention: Patient and family education
Number of subjects: 2850
Study: 24731672

Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg subcutaneous injection once weekly)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Insulin glargine (titrated to target once daily)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 456

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 456
Study: 22995705

Group type: EXPERIMENTAL
Intervention: Pentacam HR single‐camera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galilei G2 dual‐camera
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both devices
Number of subjects: 0
Study: 19540783

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) at 4±0.2 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hot Water Immersion Test (HIT) at 47±0.5 degrees C (cut-off point 5 min)
Number of subjects: 30
Study: 18953212

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study: 16006907

Group type: EXPERIMENTAL
Intervention: Cranberry juice (CBJ) 1 liter daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 24
Study: 11788983

Group type: EXPERIMENTAL
Intervention: SF-36 derived preference scores
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Directly elicited time trade off (TTO)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Choice based methods (standard gamble, TTO)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: SF-36 derived preferences
Number of subjects: 379
Study: 10469094

Group type: EXPERIMENTAL
Intervention: 950 microsec dwell time CO2 laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual tumescent dermabrasion
Number of subjects: 20
Study: 7571059

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No radiotherapy (no RT)
Number of subjects: 134
Study: 2147913

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0
Study: 7016800

Group type: EXPERIMENTAL
Intervention: EMD 21 657 (3 X 400 mg/day p.o.) + maprotiline (75 mg/day p.o.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: maprotiline (75 mg/day p.o.)
Number of subjects: 40
Study: 31103560

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 277
Study: 30449754

Group type: EXPERIMENTAL
Intervention: Telemedicine imaging of the fundus and optic nerve followed by a complete eye exam
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Complete eye exam after telemedicine screening
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Telemedicine imaging of the fundus and optic nerve
Number of subjects: 182
Study: 25995159

Group type: EXPERIMENTAL
Intervention: Cigarette Dependence Scale (CDS-5)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Cigarette Dependence (FTCD)
Number of subjects: 476
Study: 23806488

Group type: EXPERIMENTAL
Intervention: Assisted plus active cranio‐cervical flexion exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive mobilisation plus assisted cranio‐cervical flexion
Number of subjects: 18
Study: 22427507

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (individual counselling, Coping with Depression course, referral to general practitioner if indicated)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 239
Study: 20222004

Group type: EXPERIMENTAL
Intervention: Two-leg squat jumps in water
Number of subjects: 12

Group type: COMPARATOR
Intervention: Two-leg squat jumps on dry land
Number of subjects: 12
Study: 17655672

Group type: EXPERIMENTAL
Intervention: POST intervention group
Number of subjects: 330
Study: 16117464

Group type: EXPERIMENTAL
Intervention: Embol-X intra-aortic filter
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional cannulation (Control)
Number of subjects: 146
Study: 12712491

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 90 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11021961

Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Eccentric contractions
Number of subjects: 10
Study: 8615350

Group type: EXPERIMENTAL
Intervention: n‐3 LCFAs
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (LLA)
Number of subjects: 59
Study: 1333500

Group type: EXPERIMENTAL
Intervention: Diets containing 3, 6, or 9 oz of beef
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diets containing beef
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 0
Study: 6711779

Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg orally given 120-180 minutes pre-operatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg orally
Number of subjects: 100
Study: 30132204

Group type: EXPERIMENTAL
Intervention: Electronic Frailty Index (eFI) derived from electronic health records (EHRs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fried's frailty phenotype (reference standard)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Data extraction from EHRs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EHRs of patients with multiple health problems
Number of subjects: 60
Study: 29141848

Group type: EXPERIMENTAL
Intervention: MYC protein expression (top vs bottom quartile)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: MYC mRNA expression
Number of subjects: 634

Group type: COMPARATOR
Intervention: MYC protein expression
Number of subjects: 634
Study: 27815799

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) - 2 daily 1.25 g capsules (totaling about 2 g of CLA in glycerinated form)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo - 2 daily 1.25 g capsules containing sunflower oil with high oleic acid
Number of subjects: 52
Study: 24966099

Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: double HIT
Number of subjects: 52
Study: 22429192

Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 233

Group type: COMPARATOR
Intervention: Triptorelin (control)
Number of subjects: 233
Study: 20155787

Group type: EXPERIMENTAL
Intervention: Short-course RT (5 x 5 Gy) and surgery within 1 week (group 1)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Short-course RT (5 x 5 Gy) and surgery after 4-8 weeks (group 2)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Long-course RT (25 x 2 Gy) and surgery after 4-8 weeks (group 3)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Short-course RT with surgery 11-17 days after the start of RT
Number of subjects: 303

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 303
Study: 18948798

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 164
Study: 15756252

Group type: EXPERIMENTAL
Intervention: Capecitabine 1150 mg m‐2 twice daily with irinotecan 250 mg m‐2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg m‐2 with irinotecan 250 mg m‐2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: XELIRI regimen (capecitabine and irinotecan)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capecitabine and irinotecan combination therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: XELIRI regimen
Number of subjects: 27